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Abstract The aim of this study was to determine the
influence of cisplatin and novel dinuclear platinum(II)
complexes on the electrical properties of the membrane and
the level of lipid peroxidation in the human breast cancer
cell lines MDA-MB-231 and MCF-7. The basal electrical
surface properties of cells are known. Changes in cell
function may affect these surface properties, and those
changes can be detected by electrokinetic measurements.
The surface charge density of the breast cancer cell lines
MDA-MB-231 and MCF-7 were measured as a function of
pH. A four-component equilibrium model was used to
describe the interaction between the solution ions and the
breast cancer cell surface. The experimental and the theo-
retical charge variation curves of the breast cancer cells at
pH 2.5–9 were in agreement. Measurements of the cellular
malondialdehyde levels with high performance liquid
chromatography were used to determine the extent of lipid
peroxidation. The acid and base functional group concen-
trations and average association constants with hydroxyl
ions were smaller in breast cancer cell membranes treated
with cisplatin or novel dinuclear platinum(II) complexes
compared with untreated cancer cells, and the average
association constants with hydrogen ions were higher. The
levels of lipid peroxidation products in breast cancer cells
treated with cisplatin or novel dinuclear platinum(II)
complexes were also higher than in untreated cancer cells.
Keywords Surface charge density  Breast cancer cells
lines (MDA-MB-231, MCF-7)  Cisplatin  Platinum(II)
complex  Lipid peroxidation
Introduction
Biological membranes are essential boundaries within liv-
ing cells. They are multi-component structures that are
responsible for many of the physiological functions and
electrical properties of cells. Defects in any of the mem-
brane components can be manifest as changes in electric
charge as well as clinical disorders (Benga and Holmes
1984; Gennis 1989).
At the interface of the cell and the environment there is
an electric bilayer. The structure and properties of the layer
are determined by the components of the outer membrane
layer and by the equilibrium between its components and
the substances present in the environment. Any perturba-
tions in the actions of the cell are manifested by variations
in the action of the electric bilayer. An essential property of
the electric bilayer is its electrical charge, which can be
altered by cancerous transformation or by various drugs.
For these reasons, studies on the electric charge can pro-
vide information on the equilibrium within a membrane
and between the membrane and its environment, both in
physiological and in nonphysiological conditions (Do-
brzyn´ska et al. 2013; Szachowicz-Petelska et al. 2012,
2013)
Structural positive and negative charge carriers deter-
mine the electrical charge of a membrane. Positive charge
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carriers include free amino groups of proteins and amino-
phospholopids. Negative charge carriers include phospho-
lipids, especially phosphatidylserine, sialic acid, and free
carboxyl groups of proteins. Determining the electric
charge of cell membranes as a function of environmental
pH and determining the acid (CTA) and base (CTB) func-
tional group concentrations, and their average association
constants with hydrogen (KAH) or hydroxyl (KBOH) ions
can reveal changes caused by cancer transformation and
treatment with drugs (Dobrzyn´ska et al. 2006).
Platinum drugs are important anticancer compounds.
Cisplatin is widely used for the treatment of many cancers
including testicular, ovarian, bladder, cervical, head, neck,
esophageal, and small cell lung cancer (Rybak and Ram-
kumar 2007; Giaccone et al. 2004). Cisplatin reacts with
cellular components that have nucleophilic sites such as
DNA, RNA, proteins, membrane phospholipids, and thiol-
containing molecules. The interaction of cisplatin with
genomic DNA leads to adduct formation including inter-
and intra-strand DNA cross-links and DNA–protein cross-
links, which inhibit replication, transcription, and transla-
tion (Capeda et al. 2007).
The purpose of the work is to determine the influence of
cisplatin and novel dinuclear platinum(II) complexes with
the structure [Pt2L4B2] (Fig. 1) on the electrical properties
and lipid peroxidation of the cell membrane of human
breast cancer cell lines MDA-MB-231 and MCF-7. Spe-
cifically, we tested platinum complexes Pt2(isopropyl-
amine)4(berenil)2, [Pt2(L1)4B2], Pt2(piperazine)4 (berenil)2,
[Pt2(L2)4B2], Pt2(2-picoline)4 (berenil)2, [Pt2(L3)4B2],
Pt2(3-picoline)4 (berenil)2, [Pt2(L4)4B2], Pt2(4-picoline)4
(berenil)2, and [Pt2(L5)4B2]. The quantitative description
of cell membrane properties can aid in interpreting and
understanding the processes that take place on biological
membranes during cancer transformation.
Theory
The model, which has been presented in full detailed in
previous study (Dobrzyn´ska et al. 2006), assumes that
dependence of surface charge density of cell membrane on
pH of electrolyte solution can be described with the help of
four equilibria. There are two equilibria of negative groups,
with the sodium and hydrogen ions and two equilibria of the
positive groups, with the hydroxide and chloride ions. The
H?, OH- Na?, and Cl- ions are adsorbed at the cell mem-
brane (MDA-MB-231, MCF-7), and the adsorption equi-
libria (Eqs. 1–4) can by presented in the following form:
A þ Hþ , AH ð1Þ
A þ Naþ , ANa ð2Þ
Bþ þ OH , BOH ð3Þ
Bþ þ Cl , BCl ð4Þ
The association constants of the H? Na?, OH-, and Cl-














where KAH; KANa; KBOH; KBCl—association constants, aA ,
aAH, aANa, aBþ , aBOH and aBCl—surface concentrations of
corresponding groups on the membrane surface, aHþ , aNaþ ,








































Fig. 1 Structure of novel
platinum(II) complexes
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Surface charge density (d) is expressed as follows:
d ¼ ðaBþ  aAÞ  F ð9Þ
where F ¼ 96487 C=mol½  is the Faraday constant.
Functional group concentration balances are expressed
as follows:
CTA ¼ aA þ aAH þ aANa ð10Þ
CTB ¼ aBþ þ aBOH þ aBCl ð11Þ
where CTA is the total surface concentrations of acidic
groups and CTB is the total surface concentrations of basic
groups.
Elimination of aA , aAH, aBþ , and aBOH values from
above equation yields the following formula:
d
F
¼ CTB  aHþ
aHþð1þKBCl  aClÞ þ KBOH  Kw
 CTA
KAH  aHþ þ KANa  aNaþ þ 1
ð12Þ
It is difficult to solve Eq. 12 and determine the KAH, KBOH,
KANa,and KBCl constants. In cases of high or low hydrogen ion
concentrations Eq. 12 can be simplified to linear equations. In
the range of high H? concentration, the numerator of each
term in Eq. 12 can be divided by the denominator leaving two









1 þ KBCl  aCl  aH
þ





In graphical representation, the slope and the intercept
can be easily extracted. At low H? ion concentration
Eq. 12 simplified to:
d
F
¼ CTB  aHþ
KBOH  Kw þ aHþð1 þ KBCl  aClÞ
 CTA
KANa  aNaþ þ 1 þ KAH  aHþ
;
The numerator of each term should be divided by the
denominator leaving two initial terms only. These











1 þ KANa  aNaþ
þ CTB
KBOH  Kw þ
KAH  CTA
ð1 þ KANa  aNaþÞ2
 !
ð14Þ
In graphical representation, the slope and the intercept can
be easily extracted.
The coefficients estimated from the linear regression can
be used to determine CTA, CTB, KAH, and KBOH. The points
included in the regression must be carefully selected, both
in high and low pH ranges. Defining the value of these
parameters permits the calculation of the theoretical cell




The human breast cancer cell lines MCF7 and MDA-MB231
(derived by the American Type Culture Collection) were
maintained in Dulbecco’s modified Eagle’s medium con-
taining 10 % fetal bovine serum, 50 U/ml penicillin, and
50 lg/ml streptomycin. Cells were cultured in a humidified
atmosphere with 5 % CO2 at 37 C. The cells reached con-
fluence after three days and were used for the assays.
Cell suspensions, 1 9 106 cells/ml in 6 ml of culture
medium, were incubated with or without the experimental
compounds in cell culture plates. The platinum(II) com-
plexes [Pt2(L1)4B2, Pt2(L2)4B2, Pt2(L3)4B2, Pt2(L4)4B2,
and Pt2(L5)4B2] and cisplatin were added to the cultured
cells to give a final concentration 20 lM. Control cells
were incubated without test compounds. Cells from each
cell line were harvested after 12 h of incubation.
Lipid Peroxidation
The extent of lipid peroxidation in cells was assayed by
measuring malondialdehyde (MDA) levels. MDA levels
were estimated by performing a condensation reaction with
thiobarbituric acid (TBA) with MDA. The products were
separated by high performance liquid chromatography
(HPLC). In brief, 0.75 ml phosphate acid solution (0.44 M)
and 0.25 ml freshly prepared TBA solution (42 mM) were
added to 0.5 ml diluted cells, and the mixture was incubated
for 60 min at 100 C. After the mixture cooled, 0.5 ml was
neutralized with 0.5 ml 1 M methanol–1 M NaOH
(45.5:4.5; v:v). After centrifugation, 30 ll of the solution
was injected into the chromatographic column (RP18).
Separation was carried out with an isocratic elution of 40 %
methanol and 60 % phosphate buffer pH 7.0. Detection was
performed with a spectrofluorometric detector (kexcitation =
532 nm; kemission = 553 nm). The concentration of MDA
was expressed in nmoles TBA-rs/ml in the cell lysates.
Electrochemical Method
In order to determine the surface charge density of cell
membranes, cells were suspended in 0.015 M NaCl in a
measuring vessel, and electrophoretic mobility was mea-
sured using Zetasizer Nano ZS apparatus (Malvern
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Instruments). The measurements were carried out as a
function of pH. The surface charge density was determined
by the equation: r = gu/d in which u was the electropho-
retic mobility, g was the viscosity of the solution, and
d was the diffuse layer thickness (Krysin´ski and Tien
1986).
The diffuse layer thickness was determined from the





, where R was the gas
constant, T was the temperature, F was the Faraday num-
ber, I was the ionic strength of 0.9 % NaCl, and eeo was the
permeability electric medium.
Statistical Analysis
The data obtained in this study were expressed as
mean ± SD. The data were analyzed using one-way
ANOVA with Scheffe’s F test for multiple comparisons.
The values for P \ 0.05 were considered significant.
Results and Discussion
Chemotherapy plays an important role in the treatment of
breast cancer, a leading cause of cancer death among
women. This study was conducted to examine the effects of
new chemotherapeutic complexes on the electrical prop-
erties and extent of lipid peroxidation in human breast
cancer cells.
The experimental and theoretical surface charge densi-
ties of the cell membrane measured as a function of pH are
presented in Figs. 1, 2, 3, and 4. The experimental mea-
surements were indicated by points, and the theoretical
values were represented as curves. The surface charge
density dependencies of MDA-MB and MCF-7 cells on pH
produced similarly, shaped curves for all studies.
The treatment of MDA-MB cells with cisplatin or novel
dinuclear platinum(II) complexes caused a decrease in
negative charge at high/low pH values compared with
untreated cells (Figs. 2, 3). The isoelectric point of MDA-
MB cell membranes treated with cisplatin or novel dinu-
clear platinum(II) complexes shifted to higher pH values
compared with untreated MDA-MB cell membranes.
Similarly, administering cisplatin or novel dinuclear plati-
















MDA MB-231 MDA MB-231+cisplatyna MDA MB-231+L1
Fig. 2 The membrane charge density of MDA-MB-231 breast cancer
cells with and without treatment with cisplatin and Pt2(L1)4B2. The

















MDA MB-231 MDA MB-231+cisplatyna MDA MB-231+L5
Fig. 3 The membrane charge density of MDA-MB-231 breast cancer
cells with and without treatment with cisplatin and Pt2(L5)4B2. The



















Fig. 4 The membrane charge density of MCF-7 breast cancer cells
with and without treatment with cisplatin and Pt2(L1)4B2. The

















Fig. 5 The membrane charge density of MCF-7 breast cancer cells
with and without treatment with cisplatin and Pt2(L5)4B2. The
experimental values are marked by points and the theoretical ones by
line
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negative charge at high pH values and an increase in
positive charge at low pH values compared with untreated
MCF-7 cells (Figs. 4, 5). The isoelectric point of cisplatin
or novel dinuclear platinum(II) complex treated MCF-7
cell membranes shifted to higher pH values compared with
untreated MCF-7 cell membranes.
Mathematical calculations based on the four equilibria
model described the adsorption of electrolyte ions on a cell
surface membrane. We used this to enable quantitative
evaluations of the membrane parameters. The total con-
centrations of functional CTA and CTB groups was deter-
mined for treated and untreated breast cancer cell lines
MDA-MB and MCF-7. The average association constants
KAH and KBOH were calculated based on Eqs. 13 and 14.
The CTA, CTB, KAH, and KBOH constants resulting from the
calculations were substituted into Eq. 12 yielding the the-
oretical curve. Experimental points and theoretical curves
are presented in Figs. 1, 2, 3, and 4. The theoretical and
experimental surface charge density values agreed.
The experimental results indicated that cisplatin or
novel dinuclear platinum(II) complexes caused a decrease
in negative charge at the MDA-MB cell surface. This
corresponded to a decreased surface concentration of CTA
groups. Changes in functional group composition of the
MDA-MB cell membrane can be due to the appearance or
disappearance of new functional groups resulting from the
reactions with cisplatin or novel dinuclear platinum(II)
complexes. Treatment with cisplatin or novel dinuclear
platinum(II) complexes increased the association constants
of negatively charged KAH and decreased the association
constants of positively charged KBOH groups (Table 1).
The experimental results indicate that cisplatin (new
complexes) caused a decrease in negative charge numbers
at the MCF-7 cell surface. This corresponded to a decrease
surface concentration of CTA and an increased surface
concentration of CTB. Similar to MDA-MB cells, changes
in functional group composition on the membrane surface
was due to the appearance or disappearance of functional
groups on the MCF-7 cell surface. Cisplatin or new com-
plexes increased the association constants of negatively
charged KAH and decreased the association constants of
positively charged KBOH groups (Table 2). Higher changes
were observed after treatment with novel dinuclear plati-
num(II) complexes compared with cisplatin.
Table 3 shows levels of the lipid peroxidation product
MDA measured by HPLC. The treatment of MDA-MB-231
cells with cisplatin or the cisplatin complexes caused an
increase in the MDA level compared with untreated cancer
cells. Similarly, the treatment of MCF-7 cells with cisplatin
or other cisplatin complexes caused an increase in the
MDA level compared with untreated cancer cells.
Reactive oxygen species (ROS) have been reported to
play an important role in apoptosis by regulating the activity
of certain enzymes involved in the cell death pathway. Many
anticancer agents have been found to induce cancer cell
apoptosis by increasing ROS (Chen et al. 2008). Growing
evidences suggest that generation of ROS is an important
cellular event induced by chemotherapeutic drugs. Non-
published our data shown significant increase in ROS level in
the breast cancer cells after berenil–platinum(II) complexes.
Moreover, it was shown that berenil–platinum(II) complexes
are more potent antiproliferative agents than cisplatin. The
degree to which these compounds inhibited cell growth
breast cancer cells was generally consistent with their rela-
tive DNA-binding affinity, and detection of apoptosis by a
fluorescent microscopy assay revealed that novel dinuclear
platinum(II) complexes inhibited the proliferation of MCF-7
breast cancer cells by increasing the number of apoptotic and
necrotic cells (Bielawski et al. 2010; Poplawska et al. 2009).
These complexes influence cellular metabolic pathways
through the expression of transcription factor NFkB and in
consequence increased expression MAPkinases (ERK1/2,
p38) and IGF-1 and B1 integrin receptor (Bielawska et al.
2010).
Table 1 Effects of cisplatin and novel dinuclear platinum(II) complexes on CTA, CTB, KAH, and KBOH of MDA-MB-221 breast cancer cells
Groups Parameters
CTA (10
-7 mol/m2) CTB (10
-7 mol/m2) KAH (m
3/mol) KBOH (10
7 m3/mol)
MDA-MB-231 1.90 ± 0.08 1.31 ± 0.06 18.80 ± 1.08 4.97 ± 0.18
MDA-MB-231 ? cisplatin 1.58 ± 0.04a 1.48 ± 0.05a 22.81 ± 1.10a 3.97 ± 0.12a
MDA-MB-231 ? [Pt2(L1)4B2] 1.43 ± 0.07
a,b 1.63 ± 0.06a,b 32.80 ± 1.10a,b 3.62 ± 0.19a,b
MDA-MB-231 ? [Pt2(L2)4B2] 1.37 ± 0.10
a,b 1.69 ± 0.08a,b 35.41 ± 1.11a,b 3.54 ± 0.12a,b
MDA-MB-231 ? [Pt2(L3)4B2] 1.48 ± 0.10
a 1.51 ± 0.09a 28.89 ± 1.10a,b 3.81 ± 0.11a
MDA-MB-231 ? [Pt2(L4)4B2] 1.41 ± 0.10
a,b 1.59 ± 0.10a 30.72 ± 1.10a,b 3.65 ± 0.11a,b
MDA-MB-231 ? [Pt2(L5)4B2] 1.45 ± 0.06
a,b 1.62 ± 0.05a,b 32.46 ± 1.10a,b 3.67 ± 0.10a,b
p \ 0.05
a Compared with cancer cell (MDA-MB-231)
b Compared with cisplatin
I. Dobrzyn´ska et al.: Effects of Novel Dinuclear Cisplatinum(II) Complexes on the Electric Properties 171
123
Cell membrane charge is affected by sialic acid present
on glycolipids and glycoproteins and approximately 70 %
of total sialic acid is found on the cell surface. It has been
proposed that sialic acid also influences the surface con-
centration of CTA and CTB groups, as well as association
constants with the positive and negative groups during
cancer transformation and after drug treatment. The liter-
ature indicates that during cancer transformation, sialic
acid content on glycolipids and glycoproteins increases
(Oliva et al. 2006; Weigelt et al. 2005; Narayanan 1994).
The decrease of sialic acid on cancer cells after of cisplatin
or other drug treatments may be associated with an
enhanced immune response of the host. It has been sug-
gested that the loss of sialic acid decreases the surface
concentration of CTA groups and may lead to increased cell
deformity and enhanced susceptibility to phagocytosis
(Nicol and Prasad 2002).
Platinum(II) complexes preferentially attack membrane
proteins. These complexes can also interact with
phospholipids, but the bonds are relatively weak and
reversible (Gea Speelmans et al. 1996; Chu 1994). The
unstable interaction with phospholipids provokes changes
in phospholipid conformation and in the structure and
permeability of the membranes. The bond between plati-
num and monomeric proteins also provokes conformation
changes and perturbs self-association of the monomers.
The binding of platinum(II) complexes to the actin may
be one of the reasons causes cell death by cross-linking
and aggregating monomers, which depolymerizes micro-
filaments (Szachowicz-Petelska et al. 2001). Literature
date show that at the molecular level, actin is indeed
remodeled considerably in cisplatin-sensitive and cis-
platin-resistant cells (Sharma et al. 2012). The increase in
the number of apoptotic and necrotic cells after dinuclear
platinum(II) complexes confirm this suggestion, but the
reason may be also connected with changes in metabolic
pathway through the affect NFkB signaling (Poplawska
et al. 2009).
Proteins bound to DNA react with membrane phos-
pholipids. Their activity in DNA replication, transcription,
and recombination is modified by acidic phospholipids
(Sekimizu 1994). It is suggested that the changes in
membrane composition are connected with the changes in
cell membrane charge. In conclusion, new platinum(II)
complexes disturb the electrical properties and lipid per-
oxidation of cell membranes more effectively than
cisplatin.
The constants CTA, CTB, KAH, and KBOH are suitable for
monitoring the changes caused by platinum(II) drugs.
Therefore, evaluating the effects of anticancer drugs on the
cell membrane may be an important component in future
studies of cancer cell biology.
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Table 2 Effects of cisplatin and novel dinuclear platinum(II) complexes on CTA, CTB, KAH, and KBOH of MCF-7 breast cancer cells
Groups Parameters
CTA (10
-7 mol/m2) CTB (10
-7 mol/m2) KAH (m
3/mol) KBOH (10
7 m3/mol)
MCF-7 1.73 ± 0,01 1.16 ± 0,09 26.81 ± 1.10a 2.92 ± 0.11a
MCF-7 ? cisplatin 1.43 ± 0.50a 1.31 ± 0.05a 32.80 ± 1.11a 3.17 ± 0.10a
MCF-7 ? [Pt2(L1)4B2] 1.25 ± 0.06
a,b 1.71 ± 0.06a,b 48.47 ± 1.10a,b 3.82 ± 0.12a,b
MCF-7 ? [Pt2(L2)4B2] 1.31 ± 0.05
a,b 1.54 ± 0.05a,b 38.48 ± 1.12a,b 3.98 ± 0.14a,b
MCF-7 ? [Pt2(L3)4B2] 1.30 ± 0.06
a,b 1.59 ± 0.06a,b 37.52 ± 1.15a,b 3.93 ± 0.16a,b
MCF-7 ? [Pt2(L4)4B2] 1.32 ± 0.05
a,b 1.60 ± 0.07a,b 40.41 ± 1.11a,b 3.87 ± 0.12a,b
MCF-7 ? [Pt2(L5)4B2] 1.32 ± 0.04
a,b 1.61 ± 0.04a,b 39.54 ± 1.16a,b 3.92 ± 0.11a,b
p \ 0.05
a Compared with cancer cell (MCF-7)
b Compared with cisplatin
Table 3 Effect of cisplatin and novel dinuclear platinum(II) com-
plexes on the lipid peroxidation products measured as MDA in the
breast cancer cell lines MDA-MB-231 and MCF-7
Groups MDA-MB-231 MCF-7
Control 1.25 ± 0.04 10.32 ± 0.43
Cisplatin 1.43 ± 0.04a 13.75 ± 0.51a
[Pt2(L1)4B2] 1.86 ± 0.05
a,b 9.82 ± 0.41b
[Pt2(L2)4B2] 2.47 ± 0.08
a,b 8.95 ± 0.36a,b
[Pt2(L3)4B2] 1.43 ± 0.05
a 15.43 ± 0.67a,b
[Pt2(L4)4B2] 2.04 ± 0.05
a,b 8.29 ± 0.37a,b
[Pt2(L5)4B2] 2.30 ± 0.08
a,b 10.12 ± 0.45b
p \ 0.05
a Compared with cancer cell (MDA-MB-231 or MCF-7)
b Compared with cisplatin
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